Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. SK Biopharmaceuticals Co., Ltd.
  6. Summary
    A326030   KR7326030004

SK BIOPHARMACEUTICALS CO., LTD.

(A326030)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/15/2021 09/16/2021 09/17/2021 09/23/2021 09/24/2021 Date
113000 114000 113500 109500 107000 Last
195224 105664 153055 323144 224301 Volume
-1.74% +0.88% -0.44% -3.52% -2.28% Change
Estimated financial data (e)
Sales 2021 224 B 0,19 B 0,19 B
Net income 2021 -28,8 B -0,02 B -0,02 B
Net cash position 2021 359 B 0,30 B 0,30 B
P/E ratio 2021 -287x
Yield 2021 -
Sales 2022 345 B 0,29 B 0,29 B
Net income 2022 -33,5 B -0,03 B -0,03 B
Net cash position 2022 368 B 0,31 B 0,31 B
P/E ratio 2022 -406x
Yield 2022 -
Capitalization 8 380 B 7 094 M 7 106 M
EV / Sales 2021 35,8x
EV / Sales 2022 23,2x
Nbr of Employees -
Free-Float 33,7%
More Financials
Company
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business. 
Sector
Pharmaceuticals
Calendar
11/18Earnings Release
More about the company
Ratings of SK Biopharmaceuticals Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SK BIOPHARMACEUTICALS CO., LTD.
09/08SK Biopharmaceuticals' New Drugs Draw Favorable Reception in North America, Europe
MT
09/08KOSPI COMPOSITE INDEX : South Korean Stocks Fall for a Second Straight Session; SK Biophar..
MT
09/03KOSPI COMPOSITE INDEX : South Korean Stocks Close in Green on Foreign Buying Ahead of US L..
MT
09/02SK Biopharmaceuticals Expands Overseas Market for Narcolepsy Drug to Canada
MT
09/02SK Biopharmaceuticals Rolls Out Narcolepsy Treatment Drug in Canada
MT
06/17MARKET CHATTER : SK Biopharmaceuticals Launches Epilepsy Drug in Europe
MT
05/11SK Biopharmaceuticals Co., Ltd. Reports Consolidated Earnings Results for the First Qua..
CI
04/02SK IE Technology to Go Public on KOSPI in May
MT
04/01SK BIOPHARMACEUTICALS : ONTOZRY (Cenobamate) receives European Commission approval
AQ
04/01EC Clears SK Biopharmaceuticals' Epilepsy Drug Cenobamate for Sale in Europe
MT
03/17South Korea IPO boom continues as shares in vaccine firm SK Bioscience surge 30% on deb..
RE
03/08Vaccine developer SK Bioscience to raise $1.3 billion in S.Korea's largest IPO since 20..
RE
02/24S.Korea shares fall most in a month on valuation nerves, HK stamp duty hike
RE
02/24An unknown buyer agreed to acquire 10.9% stake in SK Biopharmaceuticals Co., Ltd. for K..
CI
02/07SK Biopharmaceuticals Co., Ltd. Reports Consolidated Earnings Results for the Fourth Qu..
CI
More news
News in other languages on SK BIOPHARMACEUTICALS CO., LTD.
09/08Les actions sud-coréennes chutent pour une deuxième session consécutive ; les actions d..
09/03Les actions sud-coréennes clôturent dans le vert grâce aux achats étrangers avant les d..
More news
Chart SK BIOPHARMACEUTICALS CO., LTD.
Duration : Period :
SK Biopharmaceuticals Co., Ltd. Technical Analysis Chart | A326030 | KR7326030004 | MarketScreener
Technical analysis trends SK BIOPHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 107 000,00 KRW
Average target price 131 857,14 KRW
Spread / Average Target 23,2%
EPS Revisions
Managers and Directors
Jeong-Woo Cho President, Chief Executive Officer & Director
Young-Ju Bang Independent Director
Hae-Young Ahn Independent Director
Min-Seop Song Independent Director
Geun-Joo Hwang Non-Executive Director
Sector and Competitors